This 2-period crossover study investigated the effect of calcium-phosphate-osteopontin particles on biofilm formation and pH in 48-h biofilms grown in situ. Bovine milk osteopontin is a highly phosphorylated glycoprotein that has been shown to interfere with bacterial adhesion to salivary-coated surfaces. Calcium-phosphate-osteopontin particles have been shown to reduce biofilm formation and pH drops in a 5-species laboratory model of dental biofilm without affecting bacterial viability. Here, smooth surface biofilms from 10 individuals were treated ex vivo 6 times/day for 30 min with either calcium-phosphate-osteopontin particles or sterile saline. After growth, the amount of biofilm formed was determined by confocal microscopy, and pH drops upon exposure to glucose were monitored using confocal-microscopy-based pH ratiometry. A total of 160 biofilms were analysed. No adverse effects of repeated ex vivo treatment with calcium-phosphate-osteopontin particles were observed. Particle treatment resulted in a 32% lower amount of biofilm formed (p < 0.05), but large inter-individual differences could be observed. Biofilm pH was significantly higher upon particle treatment, both shortly after the addition of glucose and after 30 min of incubation with glucose (p < 0.05). Calcium-phosphate-osteopontin particles may represent a new therapeutic approach to caries control and aim at directly targeting virulence factors involved in the caries process. Further studies are required to determine the effect of particle treatment on more acidogenic/aciduric biofilms as well as the remineralizing potential of the particles.

Keywords:
Biofilms, Calcium, Dental caries, Osteopontin, Phosphorus
1.
Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE: Defining the normal bacterial flora of the oral cavity. J Clin Microbiol 2005;43:5721-5732.
2.
Arslan SY, Leung KP, Wu CD: The effect of lactoferrin on oral bacterial attachment. Oral Microbiol Immunol 2009;24:411-416.
3.
Daims H, Lücker S, Wagner M: Daime, a novel image analysis program for microbial ecology and biofilm research. Environ Microbiol 2006;8:200-213.
4.
Danielsson Niemi L, Hernell O, Johansson I: Human milk compounds inhibiting adhesion of mutans streptococci to host ligand-coated hydroxyapatite in vitro. Caries Res 2009;43:171-178.
5.
Dawes C: What is the critical pH and why does a tooth dissolve in acid? J Can Dent Assoc 2003;69:722-724.
6.
Dige I, Baelum V, Nyvad B, Schlafer S: Monitoring of extracellular pH in young dental biofilms grown in vivo in the presence and absence of sucrose. J Oral Microbiol 2016;8:30390.
7.
Dige I, Nilsson H, Kilian M, Nyvad B: In situ identification of streptococci and other bacteria in initial dental biofilm by confocal laser scanning microscopy and fluorescence in situ hybridization. Eur J Oral Sci 2007;115:459-467.
8.
Fontana M: Enhancing Fluoride: Clinical human studies of alternatives or boosters for caries management. Caries Res 2016;50(suppl 1): 22-37.
9.
Guggenheim B, Schmid R, Aeschlimann JM, Berrocal R, Neeser JR: Powdered milk micellar casein prevents oral colonization by Streptococcus sobrinus and dental caries in rats: a basis for the caries-protective effect of dairy products. Caries Res 1999;33:446-454.
10.
Gundersen HJG, Jensen EB: The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987;147(pt 3):229-263.
11.
Kapil V, Haydar, Syed M A, Pearl V, Lundberg JO, Weitzberg E, Ahluwalia A: Physiological role for nitrate-reducing oral bacteria in blood pressure control. Free Radic Biol Med 2013;55:93-100.
12.
Kvistgaard AS, Matulka RA, Dolan LC, Ramanujam KS: Pre-clinical in vitro and in vivo safety evaluation of bovine whey derived osteopontin, Lacprodan® OPN-10. Food Chem Toxicol 2014;73:59-70.
13.
Li J, Xie X, Wang Y, Yin W, Antoun JS, Farella M, Mei L: Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review. J Dent 2014;42:769-777.
14.
Marsh PD: Controlling the oral biofilm with antimicrobials. J Dent 2010;38(suppl 1):S11-S15.
15.
Marsh PD: Contemporary perspective on plaque control. Br Dent J 2012;212:601-606.
16.
Marsh PD, Head DA, Devine DA: Ecological approaches to oral biofilms: control without killing. Caries Res 2015;49(suppl 1):46-54.
17.
Miyoshi M, Kasahara E, Park A, Hiramoto K, Minamiyama Y, Takemura S, Sato EF, Inoue M: Dietary nitrate inhibits stress-induced gastric mucosal injury in the rat. Free Radic Res 2003;37:85-90.
18.
Osso D, Kanani N: Antiseptic mouth rinses: an update on comparative effectiveness, risks and recommendations. J Dent Hyg 2013;87:10-18.
19.
Petersson J, Carlström M, Schreiber O, Phillipson M, Christoffersson G, Jägare A, Roos S, Jansson EÅ, Persson AEG, Lundberg JO, Holm L: Gastroprotective and blood pressure lowering effects of dietary nitrate are abolished by an antiseptic mouthwash. Free Radic Biol Med 2009;46:1068-1075.
20.
Prada-López I, Quintas V, Casares-De-Cal MA, Suárez-Quintanilla JA, Suárez-Quintanilla D, Tomás I: Ex vivo vs. in vivo antibacterial activity of two antiseptics on oral biofilm. Front Microbiol 2015;6:655.
21.
Reynolds EC: Remineralization of enamel subsurface lesions by casein phosphopeptide-stabilized calcium phosphate solutions. J Dent Res 1997;76:1587-1595.
22.
Sanz M, Serrano J, Iniesta M, Santa Cruz I, Herrera D: Antiplaque and antigingivitis toothpastes; in van Loveren C (ed): Toothpastes. Monogr Oral Sci. Basel, Karger, 2013, vol 23, pp 27-44.
23.
Schack L, Lange A, Kelsen J, Agnholt J, Christensen B, Petersen TE, Sørensen ES: Considerable variation in the concentration of osteopontin in human milk, bovine milk, and infant formulas. J Dairy Sci 2009;92:5378-5385.
24.
Schlafer S, Birkedal H, Olsen J, Skovgaard J, Sutherland DS, Wejse PL, Nyvad B, Meyer RL: Calcium-phosphate-osteopontin particles for caries control. Biofouling 2016;32:349-357.
25.
Schlafer S, Dige I: Ratiometric imaging of extracellular pH in dental biofilms. J Vis Exp 2016;109:e53622.
26.
Schlafer S, Garcia JE, Greve M, Raarup MK, Nyvad B, Dige I: Ratiometric imaging of extracellular pH in bacterial biofilms with C-SNARF-4. Appl Environ Microbiol 2015;81:1267-1273.
27.
Schlafer S, Meyer RL, Sutherland DS, Städler B: Effect of osteopontin on the initial adhesion of dental bacteria. J Nat Prod 2012a;75:2108-2112.
28.
Schlafer S, Raarup MK, Wejse PL, Nyvad B, Städler BM, Sutherland DS, Birkedal H, Meyer RL: Osteopontin reduces biofilm formation in a multi-species model of dental biofilm. PLoS One 2012b;7:e41534.
29.
Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-675.
30.
Takahashi N, Nyvad B: Caries ecology revisited: microbial dynamics and the caries process. Caries Res 2008;42:409-418.
31.
Teles RP, Teles FRF: Antimicrobial agents used in the control of periodontal biofilms. Effective adjuncts to mechanical plaque control? Braz Oral Res 2009;23(suppl 1):39-48.
32.
Wakabayashi H, Yamauchi K, Kobayashi T, Yaeshima T, Iwatsuki K, Yoshie H: Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. Antimicrob Agents Chemother 2009;53:3308-3316.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.